860782 | α-Glucosyl FP20
6-O-α-D-Glucopyranosyl-1β,2N,3-tridodecanoyl-D-glucosamine-4-phosphate, sodium salt
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
α-Glucosyl FP20
6-O-α-D-Glucopyranosyl-1β,2N,3-tridodecanoyl-D-glucosamine-4-phosphate, sodium salt
Introducing α‑Glucosyl FP-20 from Avanti Research™—an advanced, glycan‑modified FP‑20 sodium salt analog vaccine adjuvant compound.
α‑Glucosyl FP-20 refines immunotherapeutic agents' potency and selectivity of human Toll‑like receptor 4 (hTLR4), activating MyD88- and TRIF-mediated signals, inducing cytokine (e.g., IL‑6, TNF‑α) and type I interferon secretion, and promoting effective, balanced immune activation.
This compound functionalizes the C6 position of FP-20 sodium salt's glucosamine core with a glucose moiety while preserving a vastly scalable, reproducible, and streamlined synthetic composition.
Application
α‑Glucosyl FP-20 has various immunological research applications:
Driving antigen-specific T-cell reactions while maintaining low toxicity for immuno-oncology.
Boosting humoral and cellular immune response durability for infectious disease vaccine formulation.
Supporting receptor targeting and modulation for immunomechanistic research analyzing broad and species-specific glycan–TLR.
Enhancing safety and effectiveness of multi-adjuvant strategies that facilitate α‑Glucosyl FP-20’s synergy with agents like QS‑21.
In HEK‑Blue cell assays and macrophage polarization models, glycosylated FP‑20 derivatives’ potency demonstrably outperforms the parent FP‑20 in hTLR4 activation, thanks to their improved MD‑2 binding affinity and molecular recognition.
Recent studies show glyco‑FP‑20 derivatives triggering two crucial immune activation pathways: M1 macrophage polarization (via NF‑κB) and potent inflammasome-associated pyroptosis (RSC Publishing).
Packaging
We offer α‑Glucosyl FP-20 in 5 mg powder packaging for research applications only. It is synthesized in controlled conditions, guaranteeing high purity for every order. To request bulk pricing or sub-licensing for α‑Glucosyl FP-20, please email us at customerservice@avantilipids.com.
C48H89NNaO16P
C 58.22%, H 9.06%, N 1.41%, Na 2.32%, O 25.85%, P 3.13%
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by BiozJ. Med. Chem. 2023, 66, 4, 3010–3029Publication Date:February 2, 2023https://doi.org/10.1021/acs.jmedchem.2c01998
ACS Omega 2023, 8, 39, 36412–36417Publication Date:September 18, 2023https://doi.org/10.1021/acsomega.3c05363
J. Med. Chem. 2021, 64, 16, 12261–12272Publication Date:August 12, 2021https://doi.org/10.1021/acs.jmedchem.1c00896
- Certificate of Analysis (Lot No. 860782P-5MG-A-010 and 7279PHA010)
